The mitochondrial gatekeeper voltage-dependent anion channel 1 (VDAC1) controls metabolic and energy cross-talk between mitochondria and the rest of the cell and is involved in mitochondria-mediated apoptosis. Here, we compared the effects of downregulated VDAC1 expression in the U-87MG glioblastoma, MDA-MB-231 triple-negative breast cancer (TNBC), and A549 lung cancer cell lines, using small interfering RNA (siRNA) specific to human VDAC1 (si-hVDAC1). The cells were subjected to si-hVDAC1 (50 nM) treatment for 5–20 days. Although VDAC1 silencing occurred within a day, the cells underwent reprogramming with respect to rewiring metabolism, elimination of cancer stem cells (CSCs), and alteration of transcription factor (TF) expression and proteins associated with differentiation, with maximal changes being observed after 3 weeks of silencing VDAC1 expression. The differentiation into fewer tumorigenic cells may be associated with the elimination of CSCs. These alterations are interconnected, as protein up- or downregulation occurred simultaneously, starting 15–20 days after VDAC1 levels were first decreased. Moreover, the VDAC1 depletion-mediated effects on a network of key regulators of cell metabolism, CSCs, TFs, and other factors leading to differentiation are coordinated and are common to the glioblastoma multiforme (GBM) and lung and breast cancer cell lines, despite differing in origin and carried mutations. Thus, our study showed that VDAC1 depletion triggers reprogramming of malignant cancer cells into terminally differentiated cells and that this may be a promising therapeutic approach for various cancers.

INTRODUCTION

Cancer cells undergo reprogramming of metabolism and develop survival strategies recognized as hallmarks of cancer. Cancer cells exhibit significant metabolic alterations related to critical nutrients and substrates, such as glucose, glutamine, and oxygen, and show plasticity of the metabolic machinery. Accumulating evidence indicates that cancer cells use a combination of both glycolysis and oxidative phosphorylation (OXPHOS) to produce ATP, with the ratio depending on the prevalent normoxic or hypoxic environmental conditions.

The mitochondrial protein voltage-dependent anion channel 1 (VDAC1) mediates the fluxes of ions, nucleotides, and other metabolites (e.g., pyruvate, malate, succinate, and NADH/NAD⁺), as well as hemes, fatty acids, and cholesterol across the outer mitochondrial membrane (OMM). VDAC1 at the OMM interacts with proteins that mediate and regulate the integration of signals generated elsewhere in the cell. VDAC1 also contributes to cancer cell metabolism via the binding and channelling of mitochondrial ATP directly to hexokinase (HK), the first enzyme in glycolysis, also highly expressed in various cancers. This results in mitochondria regulating glycolytic flux with the TCA cycle and ATP synthase to fulfill the requirements of the tumor for metabolites or metabolic precursors. VDAC1 is highly expressed in different tumors, pointing to its pivotal role in regulating cancer cell energy and metabolism.

As cellular metabolic and energy reprogramming of cancer cells are essential for tumor progression, blocking energy production and the assembly of building blocks in the cancer cell is a promising anti-cancer strategy. There are currently drugs that target a single metabolic enzyme, but none that target global metabolism. VDAC1, which governs metabolic cross-talk between the mitochondria and other cell compartments and is crucial, not only for metabolic functions of the mitochondria, but also for glycolysis and other cellular metabolic processes, may represent such a target.

Using human-specific small interfering-hVDAC1 (si-hVDAC1) to silence the expression of VDAC1 reduces cellular ATP levels and cell growth, and inhibits tumor growth in lung cancer and glioblastoma multiforme (GBM). Upon treatment of GBM tumors with si-hVDAC1, the residual tumor shows reversed oncogenic properties, such as rewired metabolism and reduced angiogenesis, invasiveness, and stemness, leading to differentiation into neuron- and astrocyte-like cells. Many factors control cell differentiation, including cell...
metabolism. In addition, cancer cells do not undergo differentiation as part of their maturation, but instead, continuously proliferate.

Accumulated evidence supports the cancer stem cell (CSC) hypothesis, which suggests that a sub-population of malignant cells exhibits the stem cell properties of self-renewal and differentiation and is resistant to conventional cytotoxic/anti-proliferative therapies.12,13 CSC sub-populations have been identified in nearly all human malignancies. In GBM, CD133, SSEA1, CD49f, Musashi-1, and nestin are considered to be glioma stem cell (GSC) markers.12,14 We demonstrated a global change in tumor hallmarks upon silencing VDAC1 expression in GBM mouse models.11

Breast cancer is a heterogeneous disease with several subtypes, defined based on the presence or absence of estrogen receptors (ERs), progesterone receptors (PRs), and epidermal growth factor receptor-2, the receptor tyrosine-protein kinase erbB-2 (ERBB2/Her2). The majority (>80%) of breast cancers are ER-positive, whereas about 20% are defined as triple-negative breast cancer (TNBC), negative for ER, PR, and HER2 expression.15 There are only limited therapies for TNBC.16 Breast cancer stem-cell-specific markers include BMI-1, CD24, CD44, CD49f, aldehyde dehydrogenase (ALDH1), and EpCAM. CD24âscaled/CD44âscale/ALDH have been proposed as having high tumorigenic potential in both human primary tumors and cell lines.17-19 In human lung cancer, CSCs have also been described,20-23 with markers including the metabolic marker alcohol dehydrogenase1 (ALDH1) and the cell surface markers CD133 and CD166.24

In this study, we asked whether silencing VDAC1 expression in cultured cancer cells would result in tumors showing rewired metabolism, altered TF levels, elimination of CSCs, and induction of differentiation. This would allow us to evaluate the contribution of the tumor microenvironment to cancer cell reprogramming. Accordingly, the U-87MG glioblastoma, MDA-MB-231 TNBC, and A549 lung cancer cell lines were subjected to si-hVDAC1 treatment for 5–20 days. Although VDAC1 silencing occurred within the first day, cell reprogramming, leading to rewired metabolism, inhibited cell proliferation and stemness, altered expression of TFs, and induction of differentiation all developed with time, with maximal changes seen after 3 weeks of VDAC1 silencing. The results demonstrate that the interplay between metabolism and oncogenic signaling networks is common to GBM and lung and breast cancers, despite differing in origin and carried mutations. Our results suggest that depletion of VDAC1, serving as the bottleneck between mitochondrial and cellular metabolism, can be considered a novel strategy to target various cancers.

RESULTS

After our previous studies in a GBM mouse model demonstrated that si-hVDAC1 inhibits tumor growth, reprograms metabolism, inhibits stemness, and leads to cell differentiation,11 we asked whether similar effects would be obtained in cells in culture without the influence of the tumor microenvironment and in other cancer cell lines differing in origin and mutations carried.

VDAC1 Depletion Inhibits Cancer Cell Growth and ATP Production and Alters the Expression of Metabolic Enzymes

We initially focused on U-87MG cells, as GBM is a heterogeneous disease with a complex tumor microenvironment comprising many layers of tumor cells and normal inflammatory cells. Within this heterogeneity, the bulk tumor, proliferating cells, and cancer stem cells are found.25 Mutations in metabolic enzymes or signaling pathways directly regulating glucose and mitochondrial metabolism have been identified in GBM.26-28 Silencing of VDAC1 expression in U-87MG cells was carried out four times, every 5 days (Figure 1A), using a specific human (h)VDAC1 siRNA sequence (nt 238–256). At these times, VDAC1 expression levels were analyzed at the protein and mRNA levels (Figures 1B–1D). si-hVDAC1 markedly decreased VDAC1 protein levels (by 80%) from the first to the fourth transfections (Figure 1C). Similarly, mRNA levels were decreased by 65% following the first transfection and by 75% after the fourth transfection (Figure 1D). The si-hVDAC1 was specific to VDAC1 and had no effect on VDC2 or -3 mRNA levels (Figure 1D). Non-targeted si-RNA (NT-siRNA) had no significant effect on VDAC1 levels (Figures 1B).

Cells expressing low VDAC1 levels possessed low membrane potential (ΔΨ) (Figure 1E), low cellular ATP levels (Figure 1F), and markedly decreased cell proliferation, as assayed by the sulforhodamine B (SRB) method (Figure 1G) or by observing the expression level of the cell proliferation factor Ki-67, as analyzed by real-time qPCR (Figure 1H).

Although VDAC1 levels were decreased after the first transfection with si-hVDAC1, only after the third and fourth transfections did si-hVDAC1-treated cells show marked decreases in the expression levels of all tested metabolism-related proteins. These included glucose transporter 1 (Glut-1), hexokinase (HK-I), glyceraldehyde dehydrogenase (GAPDH), and lactate dehydrogenase-A (LDH-A), as compared with their levels in the si-NT-treated cells (Figures 2A–2C). Expression levels of the Kreb’s cycle enzyme citrate synthase (CS), mitochondrial electron transport complex IVc, and ATP synthase subunit 5a were also highly reduced in si-hVDAC1-treated cells after the third and fourth transfections, consistent with alterations in OXPHOS. Similar results were obtained at the mRNA level (Figures 2C and 2D). Glut-1 showed the highest decreases at both the mRNA and protein levels after the third transfection. Upregulated Glut-1 expression fosters enhanced aerobic glycolysis and is a common hallmark of many cancers.2

As cancer metabolism reprogramming involves interconnected signaling cascades, as, for example, mediated by the AMP-activated protein kinase (AMPK), a central regulator of cellular metabolism, energy, and redox homeostasis under various metabolic stress conditions was proposed to possess both anti- and pro-tumorigenic properties.29,30 High levels of the phosphorylated/activated AMPK (p-AMPK) protein were found in si-NT-treated cells that were highly decreased in cells transfected three and four times with si-hVDAC (Figures 2E and 2F). Thus, the decrease in the level of activated AMPK in si-hVDAC1-treated
cells (Figures 2E and 2F) is consistent with this kinase’s being a possible target for cancer prevention and treatment.31

Similar results were obtained with the phosphorylated form of ribosomal S6 (p-S6). S6 represents a mammalian target of rapamycin (mTORC1), a serine/threonine protein kinase that regulates cell growth and proliferation by integrating signals arising from growth factors, nutrients, and energy status.32,33 Thus, the decrease in the level of phosphorylated S6 (Figures 2E and 2F) suggests that mTOR kinase activity was also reduced.

Cell Treatment with si-hVDAC1 Eliminates GSCs and Induces Expression of Differentiation-Associated Proteins

To observe the effects of si-hVDAC1 silencing on GSCs, we followed several specific markers. These included nestin, a marker for CNS stem cells and SOX2, a member of SOX TF family that is predominantly expressed in immature and undifferentiated CNS cells and is important for neural stem cell proliferation and differentiation. KLF4, a member of the family of zinc-finger TFs that serve multiple functions; CD133, a cell-surface marker;34,35 nerve growth factor receptor ([NGFR] p75NTR, CD271), which plays different roles in several pathways; and ALDH1, are also considered GSC markers.

U-87GM cells treated with si-hVDAC1 showed marked decreases in the expression of these GSC markers following the third and fourth transfections, as evaluated by immunoblot (Figures 3A and 3B) and real-time qPCR (Figure 3C), which also revealed decreases in nanog mRNA levels. Immunofluorescence (IF) staining of nestin in cells treated with si-hVDAC1 was decreased, relative to si-NT-treated cells (Figure 3D), as confirmed by immunoblot and real-time qPCR (Figure 3A, 3B and 3C).

The decrease in the levels of GSC markers upon metabolism reprogramming may result from an arrest of cell proliferation (Figures 1G and 1H) and/or promotion of differentiation. Cell differentiation can be affected by altering cancer cell metabolism.36 Indeed, VDAC1 silencing in U-87MG-derived tumors resulted in tumor cell differentiation into astrocyte- and neuron-like cells.11 Here, we asked whether similar changes can be induced in U-87MG cells in culture when treated with si-hVDAC1.
Cells silenced for VDAC1 expression for 5–20 days were immuno-stained for the mature astrocyte marker glial fibrillary acidic protein (GFAP), as well as for the neuronal marker TUBB3 (Figures 4A–4D). Both proteins were found to be highly expressed in cells after 15 and 20 days of VDAC1 silencing (Figures 4A and 4B). Similar results were obtained at the mRNA level (Figure 4C). The expression of another neuronal marker, MAP2 was also increased after 15 and 20 days of VDAC1 silencing (Figure 4C). These findings were further supported by IF staining showing increased TUBB3 staining, whereas the stem cell marker, nestin staining decreased (Figure 4D), in correlation with immunoblot and real-time qPCR results (Figures 4A–4C).

Interestingly, cell morphological changes reflected in the appearance of processes were observed in the si-hVDAC1-treated cells (Figure 4D, enlargement). Next, cells subjected to a fourth transfection with si-NT- or si-hVDAC1 were stained with anti-ezrin antibodies (Figure 4E). Ezrin is a member of the ERM (ezrin-radixin-moesin) family of membrane-cytoskeleton-linking proteins, expressed in peripheral astrocytic processes in rat hippocampus, in primary cultured astrocytes and in glial tube cells. The results clearly showed changes in the morphology of si-hVDAC1-treated cells, showing long and marked processes that were not seen in the si-NT-treated cells (Figure 4E). Finally, podoplanin (PDPN) levels were decreased in si-VDAC1-treated cells, as revealed by IF (Figure 4F). PDPN expression has been described in various human tumors and has been linked to cytoskeleton regulation and thus to increased migration and invasion. These results argue that si-hVDAC1 cell treatment over time led U-87MG cells to differentiate toward mature astrocyte- and neuron-like cells.

As the major TFs p53, hypoxia-inducing factor 1α (HIF-1α), and c-mycelomatosis (c-Myc) are known to regulate metabolism, cell growth, proliferation, and differentiation, we analyzed their expression levels in cells treated with si-hVDAC1 (Figure 5). Both immunoblot and real-time qPCR demonstrated that p53 expression levels were elevated in si-hVDAC1-treated cells, whereas those of HIF-1α and c-Myc were reduced as a function of the number of transfections (Figures 5A–5C). Although p53 levels were highly increased, no apoptotic cell death was observed (data not shown).

Levels of the pro-apoptotic protein cytochrome c (Cyto c) were highly increased in the si-hVDAC1-treated cells as a function of the length of time that the cells were depleted of VDAC1, as revealed...
by immunoblot and real-time qPCR (Figures 5D and 5E). This finding can be explained by the association of Cyto c with cell differentiation and remodeling of nuclear chromatin.41,42

The results presented in Figures 1, 2, 3, 4, and 5 are summarized in Table 1, presenting the complex set of effects of VDAC1 depletion on a network of key regulators of cell metabolism, leading cancer cells toward differentiation. Most important, a reciprocal relationship between the decrease in stem cell markers and an increase in differentiation markers was obtained (Table 1).

**VDAC1 Silencing Leads to Rewired Metabolism in the A549 Lung Cancer and MBA-MD-231 Triple-Negative Breast Cancer Cell Lines**

Next, we asked whether similar effects of si-hVDAC1 as seen with U-87MG cells would also be obtained with other cancer cell lines, such as the A549 lung cancer and MBA-MD-231 TNBC cell lines (Figures 6, 7, and 8; Tables S1 and S2). A549 is a non-small cell lung carcinoma cell line derived from a primary tumor, and the cells are characterized as pre-alveolar type II pneumocytes of human lung and carry several mutations (i.e., RAS, CDKN2A, FLT3, CBL, KEAP1, ZFHX3, FH, FUS, STK11, ATR, SUFU, HIP1, and SMARCA4). MDA-MB-231 cells are derived from a pleural effusion metastatic tumor and correspond to a poorly differentiated TNBC cell line that does not express the ER, PR or ERBB2/Her2.15 These cells carry several mutations (i.e., BRAF, RAS, CDKN2A, TP53, PTEN, BRIP1 and LIFR). For comparison, the U-87MG cell line represents glioblastoma hypodiploid cells derived from a primary brain tumor and carries several mutations (i.e., CDKN2A, RAS, PTEN, HF1 and PCM1).

As with U-87MG cells, si-hVDAC1 treatment of A549 or MDA-MB-231 cells was carried out four times every 5 days (Figure 6A), with VDAC1 expression being decreased from the first transfection (Figures 6B and 6C). si-RNA downregulated VDAC1 but not VDAC2 or VDAC3 levels (Figures 6D and 6E). Mitochondria Δρ (Figure 6F) and cellular ATP levels (Figure 6G) were also decreased in both si-hVDAC1-treated cell lines.

Immunoblot and real-time qPCR analyses indicated that the energy-production-related enzymes Glut-1, HK-I, GAPDH, LDH-A, CS, electron transport subunit IVC, and ATP synthase 5a were reduced following the third and fourth transfections of MDA-MB-231 (Figures 7A–7C) and A549 (Figures S1A and S1B) cells.
Also, as with U-87MG cells, expression levels of p53 were highly elevated, whereas those of HIF-1α and c-Myc were reduced in the si-hVDAC1-treated MDA-MB-231 (Figures 7D and 7E) and A549 (Figures S1C and S1D) cells, as a function of the number of transfections.

Cell Treatment with si-hVDAC1 Eliminates CSCs and Induces Expression of Differentiation-Associated Proteins in MDA-MB-231 Breast and A549 Lung Cancer Cells

The effects of VDAC1 silencing in MDA-MB-231 cells on CSCs and differentiation was analyzed by following several specific markers of CSCs and differentiation.43 The expression of the CSC markers CD133, ALDH1, SOX2, and KLF4 were markedly decreased after the third and fourth transfections (Figures 8A and 8B). CD44+/CD24− breast cancer cells have stem/progenitor cell properties.44 In cancerous cells, CD44, a receptor of hyaluronan, metalloproteinases, and collagen types I and IV, is highly expressed, whereas CD24 is absent or expressed at low levels. si-hVDAC1 treatment of MDA-MB-231 cells resulted in downregulation of CD44 levels and upregulation of CD24 expression levels (Figure 8C).

MDA-MB-231 cells IF stained for HER2 showed increased expression levels in si-hVDAC1-treated cells, relative to its expression levels in si-NT-treated cells (Figure 8D). The expression levels of prolactin (PRL), ER, and PR were all increased in si-hVDAC1-treated cells (Figure 8E). Interestingly, PRL mRNA levels were highly increased (6- to 8-fold) following the first transfection with si-hVDAC1 (Figure 8E).

A549 cells showed decreased expression of CD133, ALDH1, SOX2, KLF4, CD44, and ABCG2, following the third and the fourth treatments with si-hVDAC1, as evaluated by immunoblot analysis (Figures S2A and S2B). IF staining confirmed the decreased expression of CD44 and ABGG2 (Figure S2C).

A549 cells are considered to be not fully differentiated alveolar epithelial type II (AT2) cells.45 AT2 cells are surfactant-producing cells expressing the pulmonary-associated surfactant proteins (SFTP) A, B, C, and D. IF staining of SFTP C expression was increased in cells treated with si-VDAC1 (Figure S2D).

AT2 cells can be differentiated into pulmonary alveolar type I (AT1) cells, characterized by the expression of podoplanin (PDPN), a membranous mucin-type sialoglycoprotein. PDPN expression levels were reduced after the first si-hVDAC1 transfection and remained low after subsequent transfections (Figure S2D and S2E). At the same time,
the levels of another AT1 marker, homeodomain only protein x (HOPX), were reduced only after the fourth transfection (Figure S2E).

These results suggest that the non-fully differentiated A549 cells had undergone reprogramming, as reflected in alterations in the expression of several proteins characterizing AT1 or AT2 cells.

The results obtained upon reprogramming of cell metabolism, leading cancer cells toward differentiation, obtained with A549 and MDA-MB-231 cells, are summarized in Tables S1 and S2, showing, as with GBM, a reciprocal relationship between the decrease in CSCs and cell differentiation.

DISCUSSION

In this study, we demonstrated that metabolic reprogramming of GBM and lung and breast cancer cells resulted in a sequence of events leading to cell differentiation into a less malignant state. We kept VDAC1 expression at low levels over time by repeated cell transfection with si-hVDAC1. The obtained results demonstrated that the cell reprogramming process induced by VDAC1 depletion, as reflected in alterations in the expression of proteins and mRNA, is dynamic over time. This time dependency was observed for both downregulated proteins, such as metabolic enzymes, CSC markers, and some TFs, and upregulated proteins, such as p53 and some of the proteins associated with cell differentiation. This reciprocal relationship suggests a link between the decrease in energy, cell growth and stem cell levels, and induced differentiation, as also found in the tumor mouse model,11,46 with its microenvironment.

Reprogramming of Cancer Cell Metabolism Induced by Silencing VDAC1 Expression

The Warburg phenotype was originally associated with weak mitochondrial activity. However, mitochondrial metabolism plays a crucial role in cancer cell survival and development, including the use of substrates, such as glutamine and/or fatty acids,47 for ATP biosynthesis, and encompasses macromolecular biosynthesis. Given the role of mitochondria in cancer cell fate, the potential to interfere with mitochondrial function is a promising avenue for treating cancer.

Here, we demonstrated such a strategy using downregulation of VDAC1 expression in cancer cells. As metabolism represents an assimilation of several signals from multiple coordinated pathways, with the mitochondria at the heart and VDAC1 being the mitochondrial gatekeeper, it is not surprising that downregulation of VDAC1 resulted in reprogrammed cell energy homeostasis, leading to reduced cell function and induced differentiation. We showed that depleting VDAC1, which is overexpressed in many tumors, including GBM and lung and breast cancers,7,9,46 resulted in a decreased expression of glycolysis-, Kreb’s cycle-, and OXPHOS-related enzymes, reflecting reduced anaplerotic and OXPHOS reactions.
has been demonstrated to be highly activated in response to hypoxic events, which leads to cell survival and metabolic reprogramming.\textsuperscript{30} VDAC1 also interacts with co-activators, and histones to stabilize gene expression and nuclear transcription machinery. Finally, the reprogramming of cancer cells is a process that develops over time; even when VDAC1 was downregulated following the differentiation of CSCs, observed in cells depleted of VDAC1, the altered expression of proteins was seen after 15–20 days of the cells being depleted of VDAC1.

### Reprogrammed Metabolism Eliminates CSCs, Possibly Via Promoting Their Differentiation

CSCs are undifferentiated cancer cells with self-renewal capacity and thus possess high tumorigenic activity and are associated with tumor resistance to anti-cancer treatments, the major cause of cancer recurrence and metastasis.\textsuperscript{51} Thus, eliminating CSCs or induction of their differentiation is required for complete eradication of tumors. Several therapeutic approaches that target CSCs via disrupting their quiescence or their resistance to oxidative stress have been proposed.\textsuperscript{51}

Here, we presented a novel mechanism for targeting CSCs that results from the rewiring of cancer cell metabolism, leading to elimination of CSCs, simultaneously leading to differentiation. The negative correlation between CSC disappearance and the appearance of differentiated cells, observed in cells depleted of VDAC1 for 15–20 days, suggests that the differentiated cells originated from CSCs.

What leads to CSC differentiation? CSCs possess a multilineage differentiation potential and can undergo dynamic and reversible changes, depending on the surrounding microenvironment, in a process defined as dynamic stemness.\textsuperscript{52} CSCs can undergo hyper-adaptation to the tumor microenvironment, as seen under hypoxia.\textsuperscript{53} Here, however, we showed that differentiation occurred not only in tumors,\textsuperscript{11,46} but also in cells in culture, suggesting that differentiation of CSCs is an intrinsic property that does not absolutely require or is induced by the microenvironment.

We demonstrated that, as in in vivo U-87MG-derived GBM tumors,\textsuperscript{11,46} the same cells originating from astroglia in culture undergo differentiation into astrocyte- and neuron-like cells. We also showed that U-87MG cell differentiation developed with time, as even when VDAC1 was downregulated following the first and second transfections with si-VDAC1, differentiation neuronal markers, such as GFAP and TUBB3, appeared only after 20 days, suggesting that the differentiated cells originated from CSCs.

### Table 1. Summary of the Expression Levels of Genes Associated with Metabolism, Stem Cells, Differentiation, and Transcription Factors as a Function of the Number of Transfections of U-87MG Cells with si-VDAC1, Relative to Transfection with si-NT (qPCR Results)

| Gene         | Fold of Change si-NT/si-VDAC1 |
|--------------|-------------------------------|
| Transfection No. | 0    | 2    | 3    | 4    |
| Metabolism    |      |      |      |      |
| Glut-1        | 1.00 ± 0.03        | −1.2 ± 0.13      | −2.90 ± 0.21      | −3.1 ± 0.23      |
| HK-1          | 1.00 ± 0.01        | −1.27 ± 0.31     | −1.5 ± 0.11       | −4.4 ± 0.21      |
| LDH-A         | 1.00 ± 0.01        | −1.2 ± 0.28      | −1.4 ± 0.08       | −3.2 ± 0.17      |
| CS            | 1.00 ± 0.01        | 1.0 ± 0.14       | −1.6 ± 0.02       | −2.8 ± 0.22      |
| ATP synthase 5a | 1.00 ± 0.01       | −1.10 ± 0.06     | −1.6 ± 0.22       | −2.5 ± 0.17      |
| VDAC1         | 1.00 ± 0.03        | −2.3 ± 0.2       | −2.8 ± 0.23       | −3.3 ± 0.07      |
| VDAC2         | 1.00 ± 0.13        | 1.2 ± 0.08       | 1.3 ± 0.32        | 1.1 ± 0.04       |
| VDAC3         | 1.00 ± 0.08        | 1.1 ± 0.07       | 0.90 ± 0.11       | 1.2 ± 0.04       |
| Stem Cell     |      |      |      |      |
| Nestin        | 1 ± 0.12           | −1.17 ± 0.07     | −1.9 ± 0.3        | −15.6 ± 0.05     |
| KLF4          | 1 ± 0.08           | 1.5 ± 0.03       | −3.9 ± 0.04       | −7.5 ± 0.06      |
| SOX2          | 1 ± 0.09           | −1.2 ± 0.03      | −5.2 ± 0.06       | −5.1 ± 0.03      |
| Nanog         | 1 ± 0.01           | −1.2 ± 0.22      | −1.2 ± 0.02       | −3 ± 0.21        |
| Differentiation|      |      |      |      |
| TUBR3         | 1 ± 0.03           | 1.6 ± 0.32       | 11.2 ± 0.7        | 13.2 ± 0.96      |
| MAP2          | 1 ± 0.02           | 1 ± 0.08         | 2.5 ± 0.37        | 3.2 ± 0.18       |
| GFAP          | 1 ± 0.01           | 1 ± 1.25         | 1.9 ± 0.55        | 3.7 ± 0.61       |
| Cyto c        | 1 ± 0.06           | 1.4 ± 0.38       | 2.5 ± 0.48        | 5.1 ± 0.28       |
| TFs           |      |      |      |      |
| p53           | 0.9 ± 0.06         | 0.9 ± 0.08       | 1.20 ± 0.08       | 4.70 ± 0.10      |
| c-Myc         | 1.0 ± 0.12         | 1.07 ± 0.04      | 1.02 ± 0.05       | −21.4 ± 0.01     |
| HIF1α         | 1.25 ± 0.12        | −1.17 ± 0.07     | −2.40 ± 0.30      | −13.9 ± 0.08     |

The changes in cell metabolism and energy production, seen upon suppressing VDAC1 expression, were also reflected in the decrease in activated AMPK levels, whose activity increases during metabolic stress conditions, controlled by ATP restriction.\textsuperscript{50} In this respect, AMPK has been demonstrated to be highly activated in vivo in human and rodent glioblastoma.\textsuperscript{48} Moreover, activation of AMPK can be a protumorigenic signal in cancer and hence a possible therapeutic target in cancer treatment.\textsuperscript{29} Furthermore, AMPK regulates many TFs, their co-activators, and histones to stabilize gene expression and nuclear events, which leads to cell survival and metabolic reprogramming.\textsuperscript{50}

Finally, AMPK is required to support tumor growth in murine Kras-dependent lung cancer models.\textsuperscript{49} Thus, these reports agree with our results showing that in the three cancers considered, high levels of activated p-AMPK in si-NT-treated cells were reduced significantly upon transfection with si-hVDAC1. Given that VDAC1 deletion rewrites cancer cell metabolism and reverses cancer cell properties to normal-like cells, the decrease in activated AMPK levels is expected.

VDAC1 depletion also affected the mTOR pathway that senses a cell’s energetic status and nutrient and oxygen levels to regulate cell growth and survival.\textsuperscript{33,50} As reflected in decreased levels of phosphorylated S6. Thus, metabolic reprogramming involves downregulation of metabolism-related enzymes and affects metabolic control via the mTOR pathway and AMP-activated protein kinase. Moreover, VDAC1 deletion resulted in similar reprogramming of cell metabolism in the three types of cancer cell lines addressed here (GBM and lung and breast cancers), regardless of cellular origin or mutations carried.

Furthermore, similar results were obtained as with sub-cutaneous U-87MG, A549, and MDA-MB-231 cell-derived xenograft mouse models,\textsuperscript{46} suggesting that the observed reprogramming is not tumor microenvironment dependent, but instead involves an intrinsic cell machinery. Finally, the reprogramming of cancer cells is a process that develops over time; even when VDAC1 expression was highly reduced one day after si-hVDAC1 treatment, the altered expression of proteins was seen after 15–20 days of the cells being depleted of VDAC1.

We demonstrated that, as in in vivo U-87MG-derived GBM tumors,\textsuperscript{11,46} the same cells originating from astroglia in culture undergo differentiation into astrocyte- and neuron-like cells. We also showed that U-87MG cell differentiation developed with time, as even when VDAC1 was downregulated following the first and second transfections with si-VDAC1, differentiation neuronal markers, such as GFAP and TUBB3, appeared only after 20 days, suggesting that the differentiated cells originated from CSCs.
the third and fourth transfections with si-hVDAC1 (15–20 days of low VDAC1 levels), concomitant with CSC elimination. Differentiated astrocyte- or neuron-like cells in culture were also reflected by the cells exhibiting neuronal morphology, as well as decreased expression of factors associated with cancer, such as PDNP.

Reprograming human glioma cells so as to convert them into terminally differentiated neuron-like cells in both culture and in adult mouse brain was demonstrated via expression of a TF functioning in neurogenesis, neurogenin 2 (NGN2), in synergy with SOX1. Our results thus suggest that glioma cells possess differentiation potential that can be activated by reprograming metabolism affecting TFs and the gene expression program.

Mammary CSCs are defined by a CD44+/CD24− phenotype. The expression of CD44, positively associated with stem cell-like characteristics was decreased, whereas that of CD24, the expression of which is related to differentiated epithelial features, was increased in si-hVDAC1-treated MDA-MB-231 cells. Furthermore, the CD44+/CD24− and ALDH1+ phenotypes were proposed to identify CSCs with distinct levels of differentiation.

In the TNBC (ER−, PR−, and HER2−) MDA-MB-231 cells, si-hVDAC1 treatment increased the expression levels of prolactin, ERs, PRs, and HER2. These changes suggest differentiation into less malignant lineages. In this respect, although existing treatment modalities are effective in treating early breast cancer, they have limited usefulness in treating the TNBCs (ER−, PR−, and HER2−). The induction of expression of these receptors in the TNBC cells upon VDAC1 depletion opens the way for hormonal and HER2-based therapy for such patients.

Similarly, we showed that, upon VDAC1 depletion in the A549 lung cancer cell line, representing non-mature AT2 cells, the expression of SFTP C was increased after the third and fourth transfections. In the case where AT2 cells differentiated into AT1 cells, we expected increased expression of PDPN, a mucin-type glycoprotein. On the contrary, PDPN expression was decreased in VDAC1-depleted cells, in line with PDPN’s presence in many types of normal cells, such as endothelial cells in lymphatic vessels, and not only in AT1 cells. In numerous types of human carcinomas, PDPN is often upregulated, particularly in squamous cell carcinomas, such as cervical, skin, and lung cancers.
PDPN is believed to play a key role in cancer cell invasiveness by controlling invadopodia, thus mediating efficient extracellular matrix degradation. It has been associated with poor prognosis and is also found on the surface of cancer-associated fibroblasts (CAFs) in lung adenocarcinomas, as well as in breast and pancreatic tumors, brain tumors, and other cancers. CAFs are correlated with an increased incidence of metastasis to lymph nodes and shorter survival times of patients. PDPN is considered as a specific lymphatic vessel marker, and since lymphangiogenesis levels are correlated with poor prognosis in cancer patients, it is proposed as a diagnostic marker. Finally, PDPN is expressed in invasive neuronal cancer stem cells. Our findings that PDPN expression is reduced in si-hVDAC1-treated cells is in line with the above pro-cancer functions of PDPN. si-hVDAC1 thus acts as an antagonist to such PDPN pro-cancer activity.

The complex set of effects resulting from VDAC1 depletion on a network of key regulators of cell metabolism, CSCs, TFs, and other factors, eventually leading cancer cells toward differentiation, indicates that all these changes are not random but rather occur as an ensemble. The changes, reflected as either up- or downregulation, occurred at the same time, starting at 15 days and further developing after 20 days, during which time VDAC1 levels were maintained at low levels.

Reprogramed Metabolism Altered TF Expression Levels and Signaling Pathways

During tumorigenesis, de-regulated TF expression or activation can promote CSC self-renewal, proliferation, and differentiation. Differentiation is a regulated process controlled via gene regulatory networks that involve TFs and epigenetics. Cell differentiation driven by reprogramming of metabolism as brought about by VDAC1 depletion is mediated via TFs, and pathways are regulated at the energy level. p53, HIF-1α, and c-Myc were shown to regulate cell metabolism, growth, proliferation, and differentiation. Starting at 15 days and further developed after 20 days of low VDAC1 levels, p53 levels were increased, whereas HIF-1α and c-Myc expression levels were reduced. p53 contributes to a diverse range of cellular functions, including regulation of DNA repair, cell cycle progression, and regulation of senescence, apoptosis differentiation, and cellular metabolism, by directly regulating glucose metabolism and OXPHOS. p53 is implicated in the regulation of differentiation in skeletal muscle, neurons, hematopoietic cells, and adipocytes. Thus, the increase in p53 expression levels seen in the three cancer cell lines tested after the third and fourth transfections with si-hVDAC1 is in accord with the function of p53 in regulating many functions, such as cellular metabolism and cell differentiation.
HIF-1α is mainly subjected to post-translational regulation via proteasome-mediated degradation. The increased stability and activation of HIF-1α in cancer cells contributes to altered glycolytic metabolism, invasion, and metastasis. The decrease in HIF-1α in si-hVDAC1-treated cell lines is thus in agreement with the observed inhibition of pro-tumorigenic properties by such treatment.

c-Myc is a TF that targets a large network of genes involved in cellular processes, such as the regulation of cell growth, proliferation, differentiation, and metabolism. c-Myc-mediated actions include driving the cellular program for glycolysis and glutaminolysis and allowing glucose-derived citrate to be used in lipid synthesis. By binding to E-boxes and recruiting histone acetyltransferases, c-Myc is capable of controlling the expression of more than 15% of human genes. The decreased c-Myc levels in cells with reduced VDAC1 levels is in line with the reprogrammed metabolism of these cells.

Thus, the altered expression of p53, c-Myc, and HIF1α resulting from VDAC1 silencing represents a central axis of cell metabolism, proliferation, and differentiation control.

In summary, the results presented here and summarized in Figure 9 show that, by downregulating VDAC1 in GBM and lung and breast cancer, we re-programmed cell energy, metabolism, and other cell functions essential for cancer cell survival. Moreover, the effects of VDAC1 depletion on a network of key regulators of cell metabolism, cancer stem cells, TFs, and other factors, finally leading to differentiation, are coordinated and are common to GBM and lung and breast cancer cell lines, despite differing in origin and carried mutations. These alterations are interconnected, as reflected in the findings that changes in protein expression levels, either the up- or downregulated, occurred simultaneously, starting after 15–20 days, during which time VDAC1 levels were maintained at low levels. Furthermore, we demonstrated that VDAC1 represents an intersection between metabolism and cancer biology, with metabolism reprogramming after VDAC1 silencing, not only inhibiting cell proliferation, but also directing the cell toward a differentiated state. Thus, our study showed that VDAC1 depletion represents a trigger for reprogramming malignant cancer cells into a post-mitotic state and probably into terminally differentiated cells and that this might be a promising therapeutic approach for various cancers.
MATERIALS AND METHODS

Materials
The cell transfection agents JetPRIME and JetPEI were obtained from PolyPlus-transfection (Illkirch, France), 2’-O-methyl-modified NT and hVDAC1-targeting siRNA were obtained from Genepharma (Suzhou, China). BSA, carbonyl cyanide-p-trifluoromethoxyphenyl-hydrazone (FCCP), SRB, Triton X-100, Tween-20, tetramethylrhodamine methylester (TMRM), and hematoxylin and eosin were obtained from Sigma (St. Louis, MO). Paraformaldehyde was purchased from EMSDIA’SUM (Hatfield, PA). DMEM was obtained from Gibco (Grand Island, NY). Normal goat serum (NGS), fetal calf serum (FCS), and the supplements L-glutamine and penicillin-streptomycin were obtained from Biological Industries (Beit Haemek, Israel). Primary antibodies, their sources, and the dilutions used are detailed in Table S3. Horseradish-peroxidase (HRP)-conjugated anti-mouse, anti-rabbit, and anti-goat antibodies were from KPL (Gaithersburg, MD). 3,3-Diaminobenzidine (DAB) was obtained from ImmPact-DAB (Burlingame, CA).

Cell Culture and Transfection
U-87MG (human glioblastoma), MDA-MB-231 (human breast carcinoma), and A549 (non-small lung carcinoma) cells were maintained at 37°C and 5% CO2 in the recommended culture medium and supplements. 2’-O-methyl-modified si-NT and si-hVDAC1/2A were synthesized by Dharmaco or were obtained from Genepharma. The sequences used with 2’-O-methyl-modified nucleotides underlined and sense (S) and anti-sense (AS) sequences are:

si-NT, S: -5’-GCAAACAUCCCAGAGGUAU-3’ and AS: 5’-AUA CCUCUGGAUGUUUGC-3’; si-hVDAC1 2/A, S: 238-5’-ACACUGAGGAGAU-3’-256 and AS: 238-5’-UAAUCUGGCCAUAGUGU-3’. Cells were seeded (150,000 cells/well) in 6-well culture dishes to 40%–60% confluence and the first transfection with 50 nM of si-NT or si-hVDAC1/2A was carried using the JetPRIME transfection reagent, according to the manufacturer’s instructions. The second, third, and fourth transfections were carried out every 5 days.

SRB Assay for Cell Proliferation
U-87MG, A549, and MDA-MB-231 cells transfected with si-NT or si-hVDAC1 one, two, three, or four times were counted and seeded in 96-well plates. After an additional 48 h, the cells were stained with SRB, as described previously.11

Immunoblot and IF
For immunostaining, proteins in cell lysates resolved by SDS-PAGE and electro-transferred to nitrocellulose membranes. These were blocked with 5% non-fat dry milk and 0.1% Tween-20 in Tris-buffered saline (TBST), and incubated with primary followed by secondary antibodies (sources and dilutions as detailed in Table S3). Enhanced chemiluminescence was used for detection of horseradish peroxidase activity. Band intensity quantitation was performed using FUSION-FX (Vilber Lourmat, Marne-la-Vallée, France) software, and values were normalized to the intensities of the appropriate β-actin signal that served as a loading control.

U-87MG, A549, and MDA-MB-231 cells, following transfection with si-NT or si-hVDAC1 one, two, three, or four times. were seeded on a coverslip and 24 h later were fixed and subjected to IF, using the appropriate antibodies (Table S3).

RNA Preparation and Real-Time qPCR
Total RNA was isolated from cells subjected to one to two transfections with si-NT or si-hVDAC1, as indicated in the figures, using the RNeasy mini kit (Qiagen) according to the manufacturer’s instructions. Total RNA quality was analyzed, complementary DNA was synthesized, and real-time qPCR was performed with specific primers (Table S4) as described previously.11 Copy numbers for each sample were calculated by the CT-based calibrated standard curve method. The results show fold changes (mean±SEM) of the three replicates.
This research was supported by the Phil and Sima Needleman

ACKNOWLEDGMENTS

This research was supported by the Phil and Sima Needleman Research Funds and Yafa and Ezra Yerucham Research Funds.

REFERENCES

1. Wenger, J.R., Chun, S.Y., Dang, D.T., Luesch, H., and Dang, L.H. (2011). Combination therapy targeting cancer metabolism. Med. Hypotheses 76, 169–172.
2. Cairns, R.A., Harris, I.S., and Mak, T.W. (2011). Regulation of cancer cell metabolism. Nat. Rev. Cancer 11, 85–95.
3. Turcotte, M.L., Parliament, M., Franko, A., and Allalunis-Turner, J. (2002). Variation in mitochondrial function in hypoxia-sensitive and hypoxia-tolerant human glioma cells. Br. J. Cancer 86, 619–624.
4. Wolf, A., Aguihiotri, S., and Guha, A. (2010). Targeting metabolic remodeling in glioblastoma multiforme. Oncotarget 1, 552–562.
5. Majeed, R.H.A., Qurishi, Y., Qazi, A.K., Hussain, A., Ahmed, M., Najar, R.A., Bhat, J.A., Singh, S.K., and Saxena, A.K. (2012). Therapeutic Targeting of Cancer Cell Metabolism: Role of Metabolic Enzymes, Oncogenes and Tumor Suppressor Genes. J. Cancer Sci. Ther. 4, 281–291.
6. Shoshan-Barmatz, V., De Pinto, V., Zweckstetter, M., Raviv, Z., Keinan, N., and Arbel, N. (2010). VDAC, a multi-functional mitochondrial protein regulating cell life and death. Mol. Aspects Med. 31, 227–285.
7. Shoshan-Barmatz, V., Ben-Hail, D., Admoni, L., Krelin, Y., and Tripathi, S.S. (2015). The mitochondrial voltage-dependent anion channel 1 in tumor cells. Biochim. Biophys. Acta 1848, 2547–2575.
8. Shoshan-Barmatz, V., Krelin, Y., Shteinifer-Kuzmine, A., and Arif, T. (2017). Voltage-Dependent Anion Channel 1 As an Emerging Drug Target for Novel Anti-Cancer Therapeutics. Front. Oncol. 7, 154.
9. Arif, T., Vasilkovsky, L., Refaely, Y., Konson, A., and Shoshan-Barmatz, V. (2014). Silencing VDAC1 Expression by siRNA Inhibits Cancer Cell Proliferation and Tumor Growth In Vivo. Mol. Ther. Nucleic Acids 3, e159.
10. Abu-Hamad, S., Sivan, S., and Shoshan-Barmatz, V. (2006). The expression level of the voltage-dependent anion channel controls life and death of the cell. Proc. Natl. Acad. Sci. USA 103, 5787–5792.
11. Arif, T., Krelin, Y., Nakdimon, I., Benharroch, D., Paul, A., Dadon-Klein, D., and Shoshan-Barmatz, V. (2017). VDAC1 is a molecular target in glioblastoma, with its depletion leading to reprogrammed metabolism and reversed oncogenic properties. Neuro Oncol. 19, 951–964.
12. Visvader, J.E., and Lindeman, G.J. (2012). Cancer stem cells: current status and evolving complexities. Cell Stem Cell 10, 717–728.
13. Oskarsson, T., Battle, E., and Massague, J. (2014). Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell 14, 306–321.
14. Yuan, X., Curtin, J., Xiong, Y., Liu, G., Waschmann-Hogiu, S., Farkas, D.L., Black, K.L., and Yu, J.S. (2004). Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 23, 9392–9400.
15. Rakha, E.A., El-Sayed, M.E., Green, A.R., Lee, A.H., Robertson, J.F., and Ellis, I.O. (2007). Prognostic markers in triple-negative breast cancer. Cancer 109, 25–32.
16. Cleator, S., Heller, W., and Coombes, R.C. (2007). Triple-negative breast cancer: therapeutic options. Lancet Oncol. 8, 235–244.
17. Ginestier, C., Hur, M.H., Charafe-Jauffret, E., Monville, F., Dutcher, J., Brown, M., Jacquemier, J., Viens, P., Kleer, C.G., Liu, S., et al. (2007). ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1, 555–567.
18. Charafe-Jauffret, E., Ginestier, C., Bertucci, F., Cabaud, O., Wicinski, J., Finetti, P., Josselin, E., Adeleide, J., Nguyen, T.T., Monville, F., et al. (2013). ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program. Cancer Res. 73, 7290–7300.
19. Charafe-Jauffret, E., Ginestier, C., Iovino, F., Tarpin, C., Diebel, M., Esterni, B., Houvenaeghel, G., Extra, J.M., Bertucci, F., Jacquemier, J., et al. (2010). Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin. Cancer Res. 16, 45–55.
20. Jiang, F., Qiu, Q., Khanna, A., Todd, N.W., Deepak, J., Xing, L., Wang, H., Liu, Z., Su, Y., Stass, S.A., and Katz, R.L. (2009). Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol. Cancer Res. 7, 330–338.
21. O’Flaherty, I.D., Barr, M., Fennell, D., Richard, D., Reynolds, J., O’Leary, J., and O’Byrne, K. (2012). The cancer stem-cell hypothesis: its emerging role in lung cancer biology and its relevance for future therapy. J. Thorac. Oncol. 7, 1880–1890.
22. Erizzo, A., Lotti, F., Sette, G., Polazzi, E., Biffoni, M., Di Virgilio, A., Conticello, C., Ruco, L., Peschle, C., and De Maria, R. (2008). Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 15, 504–514.
23. Ho, M.M., Ng, A.V., Lam, S., and Hung, J.Y. (2007). Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 67, 4827–4833.
24. Miyata, T., Yoshimatsu, T., So, T., Oyama, T., Uramoto, H., Osaki, T., Nakaniishi, R., Tanaka, F., Nagaya, H., and Gotoh, A. (2015). Cancer stem cell markers in lung cancer. Personalized Medicine Universe 4, 40–45.
25. Bonavia, R., Inda, M.M., Cavenne, W.K., and Furnari, F.B. (2011). Heterogeneity maintenance in glioblastoma: a social network. Cancer Res. 71, 4055–4060.
26. TCGA Research Network (2013). The somatic genomic landscape of glioblastoma. Cell 155, 462–477.
27. Network, T.C. (2013). Corrigendum: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 494, 506.
28. Parsons, D.W., Jones, S., Zhang, X., Lin, J.C., Leary, R.J., Angenendt, P., Mankoo, P., Carter, H., Stu, I.M., Gallia, G.L., et al. (2008). An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1070–10712.
29. Jeon, S.M., and Hay, N. (2015). The double-edged sword of AMPK signaling in cancer and its therapeutic implications. Arch. Pharm. Res. 38, 346–357.
30. Sanli, T., Steinberg, G.R., Singh, G., and Tsekkridis, T. (2014). AMP-activated protein kinase (AMPK) beyond metabolism: a novel genomic stress sensor participating in the DNA damage response pathway. Cancer Biol. Ther. 15, 156–169.
31. Li, W., Sood, M.Y., Young, M.R., Chen, G., and Hua, B. (2015). Targeting AMPK for cancer prevention and treatment. Oncotarget 6, 7365–7378.
32. Wullschlegler, S., Loewith, R., and Hall, M.N. (2006). TOR signaling in growth and metabolism. Cell 124, 471–484.
33. Guertin, D.A., and Sabatini, D.M. (2007). Defining the role of mTOR in cancer. Cancer Cell 12, 9–22.
34. Galli, R., Bind, E., Orfandli, U., Cipolletti, B., Gritt, A., De Vitis, S., Fiocco, R., Foroni, C., Dimeo, F., and Vescovi, A. (2004). Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 64, 7011–7021.
35. Singh, S.K., Hawkins, C., Clarke, I.D., Squire, J.A., Bayani, J., Hide, T., Henkelman, R.M., Cubisano, M.D., and Dirks, P.B. (2004). Identification of human brain tumour initiating cells. Nature 432, 396–401.
36. Xavier, J.M., Morgado, A.L., Sola, S., and Rodrigues, C.M. (2014). Mitochondrial translocation of p53 modulates neuronal fate by preventing differentiation-induced mitochondrial stress. Antioxid. Redox Signal. 21, 1009–1024.

37. Derouiche, A., and Frotscher, M. (2001). Peripheral astrocyte processes: monitoring by selective immunostaining for the actin-binding ERM proteins. Glia 36, 330–341.

38. Cleary, M.A., Ubah, N., Picciotto, M.R., and Beech, R.D. (2006). Expression of ezrin in glial tubules in the adult subventricular zone and rostral migratory stream. Neuroscience 143, 851–861.

39. Mishima, K., Kato, Y., Kaneko, M.K., Nishikawa, R., Hirose, T., and Matsutani, M. (2006). Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol. 111, 483–488.

40. Yeung, S.J., Pan, J., and Lee, M.H. (2008). Roles of p53, MYC and HIF-1 in regulating tumor cell fate. Biochim. Biophys. Acta 1787, 847–856.

41. Nur-E-Kamal, A., Gross, S.R., Pan, Z., Balklava, Z., Ma, J., and Liu, L.F. (2004). Nuclear translocation of mitochondrial cytochrome c during apoptosis. J. Biol. Chem. 279, 24914–24919.

42. Zhao, S., Aviles, E.R., Jr., and Fujikawa, D.G. (2010). Nuclear translocation of mitochondrial cytochrome c, lysosomal cathepsins B and D, and three other death-promoting proteins within the first 60 minutes of generalized seizures. J. Neurosci. Res. 88, 1727–1737.

43. Lin, V.C., Jin, R., Tan, P.H., Aw, S.E., Woon, C.T., and Bay, B.H. (2003). Progesterone induces cellular differentiation in MDA-MB-231 breast cancer cells transfected with progesterone receptor complementary DNA. Am. J. Pathol. 162, 1781–1787.

44. Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J., and Clarke, M.F. (2003). Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 100, 10001–10006.

45. Mao, P., Wu, S., Li, J., Fu, W., He, W., Liu, X., Slutsky, A.S., Zhang, H., and Li, Y. (2005). AMPK activation by oncogenesis is required to maintain cancer cell proliferation. Int. J. Cancer 116, 2638–2646.

46. Eichner, L.J., Brun, S.N., Herzig, S., Young, N.P., Curtis, S.D., Shackelford, D.B., Shokhirev, M.N., Leblanc, M., Vera, L.I., Hutchins, A., et al. (2019). Genetic Analysis Reveals AKAPs Is Required to Support Tumor Growth in Murine Kras-Dependent Lung Cancer Models. Cell Metab. 29, 285–302.e7.

47. Meytah, O. (2015). Ribosomal Protein S6 Phosphorylation: Four Decades of Research. Int. Rev. Cell Mol. Biol. 320, 41–73.

48. Yoshida, G.J., and Saya, H. (2016). Therapeutic strategies targeting cancer stem cells. Cancer Sci. 107, 5–11.

49. Islam, F., Qiao, B., Smith, R.A., Gopalan, V., and Lam, A.K. (2015). Cancer stem cell: fundamental experimental pathological concepts and updates. Exp. Mol. Pathol. 98, 184–191.

50. Park, S.Y., Lee, H.E., Li, H., Shipitsin, M., Gelman, R., and Polyak, K. (2010). Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin. Cancer Res. 16, 876–887.

51. Arif, T., Paul, A., Krelin, Y., Shteinfier-Kuzmine, A., and Shoshan-Barmatz, V. (2018). Progesterone induces cellular differentiation in MDA-MB-231 breast cancer cells transfected with progesterone receptor complementary DNA. Am. J. Pathol. 162, 1781–1787.

52. Xu, Z., Zang, T., Liu, M.L., Wang, L.L., Niu, W., and Zang, C.L. (2014). Reprogramming the fate of human glioma cells to impede brain tumor development. Cell Death Dis. 5, e1463.

53. Ríos, M., Foretz, M., Viollet, B., Prieto, A., Fraga, M., Costoya, J.A., and Señarís, R. (2015). Podoplanin-expressing cancer-associated fibroblasts lead and enhance the local invasion of cancer cells in lung adenocarcinoma. Int. J. Cancer 137, 784–796.

54. Meyuhas, O. (2015). Ribosomal Protein S6 Phosphorylation: Four Decades of Research. Int. Rev. Cell Mol. Biol. 320, 41–73.

55. Plaks, V., Kong, N., and Werb, Z. (2015). The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell 16, 225–238.

56. Liu, L.F., Pan, Z., Balklava, Z., Ma, J., and Nur-E-Kamal, A. (2004). Nuclear translocation of mitochondrial cytochrome c during apoptosis. J. Biol. Chem. 279, 24914–24919.

57. Zhao, S., Aviles, E.R., Jr., and Fujikawa, D.G. (2010). Nuclear translocation of mitochondrial cytochrome c, lysosomal cathepsins B and D, and three other death-promoting proteins within the first 60 minutes of generalized seizures. J. Neurosci. Res. 88, 1727–1737.

58. Liu, L.F., Pan, Z., Balklava, Z., Ma, J., and Nur-E-Kamal, A. (2004). Nuclear translocation of mitochondrial cytochrome c during apoptosis. J. Biol. Chem. 279, 24914–24919.

59. Meytah, O. (2015). Ribosomal Protein S6 Phosphorylation: Four Decades of Research. Int. Rev. Cell Mol. Biol. 320, 41–73.

60. Wang, R., Dillon, C.P., Shi, L.Z., Milasta, S., Carter, R., Finkelstein, D., McCormick, F., and Shokhirev, M.N., Leblanc, M., Vera, L.I., Hutchins, A., et al. (2019). Genetic Analysis Reveals AKAPs Is Required to Support Tumor Growth in Murine Kras-Dependent Lung Cancer Models. Cell Metab. 29, 285–302.e7.

61. Meytah, O. (2015). Ribosomal Protein S6 Phosphorylation: Four Decades of Research. Int. Rev. Cell Mol. Biol. 320, 41–73.

62. Xu, Z., Zang, T., Liu, M.L., Wang, L.L., Niu, W., and Zang, C.L. (2014). Reprogramming the fate of human glioma cells to impede brain tumor development. Cell Death Dis. 5, e1463.

63. Ríos, M., Foretz, M., Viollet, B., Prieto, A., Fraga, M., Costoya, J.A., and Señarís, R. (2015). Podoplanin-expressing cancer-associated fibroblasts lead and enhance the local invasion of cancer cells in lung adenocarcinoma. Int. J. Cancer 137, 784–796.

64. Meyuhas, O. (2015). Ribosomal Protein S6 Phosphorylation: Four Decades of Research. Int. Rev. Cell Mol. Biol. 320, 41–73.

65. Wang, R., Dillon, C.P., Shi, L.Z., Milasta, S., Carter, R., Finkelstein, D., McCormick, F., and Shokhirev, M.N., Leblanc, M., Vera, L.I., Hutchins, A., et al. (2019). Genetic Analysis Reveals AKAPs Is Required to Support Tumor Growth in Murine Kras-Dependent Lung Cancer Models. Cell Metab. 29, 285–302.e7.